FDA Approval of Daratumumab in High Risk Smoldering Myeloma: AQUILA by Dr. Vincent Rajkumar

In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention.

Key topics discussed included:
• The definition and classification of smoldering myeloma
• The design and findings of the AQUILA trial
• The significance of time to progression and overall survival in treatment
• The risk-benefit analysis of daratumumab therapy, including potential side effects
• Future directions in myeloma treatment and ongoing research

Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!